¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Diffuse mesangiocapillary glomerulonephritis"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • mesangial proliferative glomerulonephritis
    Ç÷°ü»çÀÌÁúÁõ½ÄÅ丮ÄáÆÏ¿°, Ç÷°ü°£¼¼Æ÷Áõ½Ä»ç±¸Ã¼½Å¿°
  • poststreptococcal glomerulonephritis
    »ç½½¾Ë±Õ°¨¿°ÈÄÅ丮ÄáÆÏ¿°, ¿¬¼â±¸±Õ°¨¿°ÈĻ籸ü½Å¿°
  • rapidly progressive glomerulonephritis
    ±Þ¼ÓÁøÇàÅ丮ÄáÆÏ¿°, ±Þ¼ÓÁøÇà»ç±¸Ã¼½Å¿°
  • degenerative diffuse cerebral sclerosis
    ÅðÇ౤¹üÀ§´ë³ú°æÈ­(Áõ)
  • diffuse
    ±¤¹üÀ§-, È®»ê-, ¹Ì¸¸-
  • diffuse aneurysm
    ±¤¹üÀ§µ¿¸ÆÀÚ·ç, ±¤¹üÀ§µ¿¸Æ·ù
  • diffuse arteriosclerosis
    ±¤¹üÀ§µ¿¸Æ°æÈ­(Áõ)
  • diffuse atelectasis
    ±¤¹üÀ§¹«±âÆó
  • diffuse cerebral sclerosis
    ±¤¹üÀ§´ë³ú°æÈ­Áõ
  • diffuse cutaneous mastocytosis
    ±¤¹üÀ§ÇǺκñ¸¸¼¼Æ÷Áõ
  • diffuse esophageal spasm
    ±¤¹üÀ§½Äµµ¿¬Ãà
  • diffuse goiter
    ±¤¹üÀ§°©»ó»ùÁ¾
  • diffuse inflammation
    ±¤¹üÀ§¿°Áõ
  • diffuse intravascular coagulation
    ±¤¹üÀ§Ç÷°ü³»ÀÀ°í
  • diffuse large B-cell lymphoma
    ±¤¹üÀ§Å«B¼¼Æ÷¸²ÇÁÁ¾
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • diffuse aneurysm
    ±¤¹üÀ§µ¿¸ÆÀÚ·ç, ±¤¹üÀ§µ¿¸Æ·ù
  • diffuse arteriosclerosis
    ±¤¹üÀ§µ¿¸Æ°æÈ­Áõ
  • diffuse atelectasis
    ±¤¹üÀ§¹«±âÆó
  • diffuse intravascular coagulation
    ¹Ì¸¸Ç÷°ü³»ÀÀ°í
  • diffuse
    ±¤¹üÀ§-, È®»ê-, ¹Ì¸¸-
  • degenerative diffuse cerebral sclerosis
    ÅðÇ౤¹üÀ§³ú°æÈ­(Áõ)
  • diffuse erythema
    ±¤¹üÀ§È«¹Ý
  • diffuse goiter
    ¹Ì¸¸°©»ó»ùÁ¾, ±¤¹üÀ§¹æÆÐ»ùÁ¾
  • diffuse inflammation
    ¹Ì¸¸¿°Áõ
  • diffuse placenta
    ÆÛÁøÅ¹Ý
  • diffuse reflection
    ¹Ì¸¸¼º¹Ý»ç
  • diffuse scleritis
    ±¤¹üÀ§°ø¸·¿°
  • diffuse scleroderma
    ±¤¹üÀ§ÇǺΰæÈ­Áõ
  • diffuse sclerosis
    ±¤¹üÀ§°æÈ­Áõ
  • diffuse cerebral sclerosis
    ±¤¹üÀ§³ú°æÈ­Áõ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • proliferative glomerulonephritis
    Áõ½Ä¼º »ç±¸Ã¼½Å¿°(ñòãÖàõ ÞêϹô÷ãìæú)
  • rapidly progressive (crescentic) glomerulonephritis
    ±Þ¼ÓÁøÇ༺»ç±¸Ã¼½Å¿°(ÐááÜòäú¼àõÞêϹô÷ãìæú)
  • rapidly progressive glomerulonephritis
    ±Þ¼ÓÁøÇ༺ »ç±¸Ã¼½Å¿°.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • glomerulonephritis,focal proliferative
    ÃÊÁ¡¼º Áõ½Ä¼º
  • glomerulonephritis,membranoproliferative
    ¸·Áõ½Ä¼º
  • glomerulonephritis,membranous
    ¸·¼º
  • intercapillary glomerulonephritis
    ¸ð¼¼(Ç÷)°ü°£»ç±¸Ã¼½Å¿°.
  • membranous glomerulonephritis
    ¸·¼º»ç±¸ ü½Å¿°(¡­ÞêϹô÷ãìæú).
  • membranous glomerulonephritis
    ¸·¼º»ç±¸Ã¼½Å¿°(¡­Þêϳô÷ãìæú)
  • poststreptococcal(proliferative) glomerulonephritis
    ¿¬¼â»ó±¸±Õ°¨¿°ÈÄ(Áõ½Ä¼º) »ç±¸Ã¼½Å¿°(ææáðßÒϹжÊïæøý­(ñòãÖàõ) ÞêϹô÷ãìæú)
  • proliferative glomerulonephritis
    Áõ½Ä¼º »ç±¸Ã¼½Å¿°(ñòãÖàõ ÞêϹô÷ãìæú)
  • rapidly progressive (crescentic) glomerulonephritis
    ±Þ¼ÓÁøÇ༺»ç±¸Ã¼½Å¿°(ÐááÜòäú¼àõÞêϹô÷ãìæú)
  • rapidly progressive glomerulonephritis
    ±Þ¼ÓÁøÇ༺ »ç±¸Ã¼½Å¿°.
  • subacute glomerulonephritis
    ¾Æ±Þ¼º »ç±¸Ã¼½Å¿°(¡­ÞêϹô÷ãìæú).
  • subacute glomerulonephritis
    ¾Æ±Þ¼º »ç±¸Ã¼½Å¿°(¡­ÞêϹô÷ãìæú)
  • degenerative diffuse cerebral sclerosis
    ÅðÇ༺ ¹Ì¸¸¼º ³ú°æÈ­(Áõ)(¡­Ú¯Ø·àõ ÒàÌãûùñø).
  • diffuse
    ¹Ì¸¸¼º, »êÀ缺
  • diffuse abscess
    ¹Ì¸¸¼º ³ó¾ç(¡­³ó¾ç).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
DILD diffuse infiltrative lung disease; diffuse interstitial lung disease
AGN acute glomerulonephritis; agnosia
APSGN acute poststreptococcal glomerulonephritis
CG cardiography; cardiogreen; choking gas; choriogenic gynecomastia; chorionic gonadotropin; chromogran...
CGN chronic glomerulonephritis
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CGN Chronic glomerulonephritis
CGN Crescentic glomerulonephritis
CrGN Crescentic glomerulonephritis
EAG Experimental autoimmune glomerulonephritis
iMGN Idiopathic membranous glomerulonephritis
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
  • N05.5
    Diffuse mesangiocapillary glomerulonephritis
    ¹Ì¸¸¼º ¸Þ»êÁöÀ½ ¸ð¼¼Ç÷°ü¼º »ç±¸Ã¼½Å¿°
  • N06.5
    Diffuse mesangiocapillary glomerulonephritis
    ¹Ì¸¸¼º ¸Þ»êÁöÀ½ ¸ð¼¼Ç÷°ü¼º »ç±¸Ã¼½Å¿°
  • N07.5
    Diffuse mesangiocapillary glomerulonephritis
    ¹Ì¸¸¼º ¸Þ»êÁöÀ½ ¸ð¼¼Ç÷°ü¼º »ç±¸Ã¼½Å¿°
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • diffuse panbronchiolitis
    ¹Ì¸¸¼º ¹ü¼¼±â°üÁö¿°
    ÀϺ»¿¡¼­ ÈçÈ÷ Áø´ÜµÇ´Â È£Èí ¼¼±â°üÁöÀÇ Æ¯¹ß¼º ÁúȯÀÌ´Ù. ¹Ì±¹¿¡¼­´Â ¾ÆÁÖ µå¹°´Ù. ¿©ÀÚº¸´Ù ³²ÀÚ¿¡¼­ 2¹è ¸¹À¸¸ç, ¿¬·ÉÀº 20-80¼¼¿¡¼­ ¹ß»ýÇÑ´Ù. ȯÀÚÀÇ ´ë´Ù¼ö´Â ¸¸¼º ºÎºñµ¿¿°ÀÇ º´·ÂÀÌ ÀÖ´Ù. ½ÉÇÑ È£Èí°ï¶õ, ±âħ, °´´ã »ý»ê µîÀÌ Áß¿äÇÑ ÀÓ»ó Áõ»óÀÌ´Ù. ûÁøÇÏ¸é Æó¿¡¼­ ¼öÆ÷À½°ú ÅëÀ½ÀÌ µé¸®¸ç Æó ±â´É °Ë»ç¸¦ ÇÏ¸é Æó¼â¼º Æó ±â´É º¯È­¸¦ º¼ ¼ö ÀÖ´Ù. ÈäºÎ ¹æ»ç¼± »çÁø»ó Ư¡ÀûÀÎ ¹Ì¸¸¼º ¼Ò°áÀý À½¿µ°ú °úÆØÃ¢À» º¼ ¼ö ÀÖ´Ù. Áø´Ü¿¡´Â °³Èä Æó »ý°ËÀÌ ÇÊ¿äÇÒ ¼ö ÀÖ´Ù.
  • diffuse peritonitis
    ¹Ì¸¸¼º º¹¸·¿°, ¹ü¹ß¼º º¹¸·¿°, »êÀ缺 º¹¸·¿°
    º¹¸·ÀÇ ¾î¶² ºÎÀ§¿¡¸¸ ÇÑÁ¤ÇÏÁö ¾Ê°í ³ÐÀº ¹üÀ§·Î ħ¹üÇÑ ¿°Áõ.
  • diffuse projection
    ±¤¹ü¼º Åõ»ç
  • diffuse redness
    ¹Ì¸¸¼º ¹ßÀû
  • diffuse sclerosis
    ¹ü¹ß¼º °æÈ­Áõ
  • diffuse thickening
    ¹Ì¸¸¼º ºñÈÄ
  • diffuse waxy spleen
    ¹Ì¸¸¼º ³³ ºñ
    ºñÀåÀÇ ¾Æ¹Ð·ÎÀÌµå º¯¼ºÀ¸·Î¼­ ƯÈ÷ Á¤¸Æµ¿ÀÇ ¿ÜÃþ°ú ¸Á»ó Á¶Á÷ÀÌ Ä§½ÀµÈ °Í.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
mesangial proliferative glomerulonephritis <nephrology, pathology> Inflammation of the kidney glomerulus (blood filtering portion of the kidney) due to the abnormal deposition of IgM antibody in the mesangium layer of the glomerular capillary. A form of glomerulonephritis that appears to be caused by an abnormal immune response. This disorder generally manifests as nephrotic syndrome.
Symptoms include swelling, dark urine, weight gain, hypertension, anorexia and bloody urine.
Acronym: MPGN
(05 Jan 1998)
chronic glomerulonephritis Glomerulonephritis that presents with persisting proteinuria, chronic renal failure, and hypertension, of insidious onset or as a late sequel of acute glomerulonephritis; the kidneys are symmetrically contracted and granular, with scarring and loss of glomeruli and the presence of tubular atrophy and interstitial fibrosis.
Synonym: chronic nephritis.
(05 Mar 2000)
crescentic glomerulonephritis <nephrology, pathology> A relatively uncommon (affecting 1 out of 10,000 people) form of acute glomerulonephritis that results in damage within the glomerulus of the kidney. There is rapid loss of kidney function with the formation of crescents on microscopic analysis (kidney biopsy). This disorder may result in acute glomerulonephritis or nephrotic syndrome, but ultimately results in renal failure and end-stage renal disease.
Symptoms include smoky coloured urine (pyuria), decreased urine output, swelling and hypertension. Any conditions which can cause a vasculitis increase the risk of this disorder. Some examples include lupus, Goodpasture's syndrome, Henoch-Schonlein purpura, IgA nephropathy, membranoproliferative glomerulonephritis, anti-glomerular basement membrane antibody disease, history for malignant tumours and exposure to hydrocarbon solvents.
(27 Sep 1997)
proliferative glomerulonephritis Glomerulonephritis with hypercellularity of glomeruli due to proliferation of endothelial or mesangial cells, occurring in acute glomerulonephritis and membranoproliferative glomerulonephritis.
(05 Mar 2000)
segmental glomerulonephritis Glomerulonephritis affecting only part of a glomerulus or glomeruli.
Synonym: local glomerulonephritis.
(05 Mar 2000)
hypocomplementemic glomerulonephritis <pathology> A kidney disorder which results in kidney dysfunction. Inflammation of the glomeruli result from an abnormal immune response and the deposition of antibodies within the kidney (glomerulus) ultrastructure.
Membranoproliferative glomerulonephritis has been divided into two different types in the basis of where the antibodies are deposited in the glomerulus. MPGN type I, the more common type, deposits antibodies in the subendothelial layer of the basement membrane, whereas type II deposits antibodies in the bottom layer of the basement membrane.
Symptoms include cloudy urine (pyuria), decreased urine output, swelling and hypertension. This disorder often results in end-stage renal disease.
Acronym: MPGN
(26 Mar 1998)
necrotising glomerulonephritis <pathology> A relatively uncommon (affecting 1 out of 10,000 people) form of acute glomerulonephritis that results in damage within the glomerulus of the kidney. There is rapid loss of kidney function with the formation of crescents on microscopic analysis (kidney biopsy). This disorder may result in acute glomerulonephritis or nephrotic syndrome, but ultimately results in renal failure and end-stage renal disease.
Symptoms include smoky coloured urine (pyuria), decreased urine output, swelling and hypertension. Any conditions which can cause a vasculitis increase the risk of this disorder. Some examples include lupus, Goodpasture's syndrome, Henoch-Schonlein purpura, IgA nephropathy, membranoproliferative glomerulonephritis, anti-glomerular basement membrane antibody disease, history for malignant tumours and exposure to hydrocarbon solvents.
(27 Sep 1997)
subacute glomerulonephritis Undesirable term for glomerulonephritis with proteinuria, haematuria and azotemia persisting for many weeks; renal changes are variable, including those of rapidly progressive and membranoproliferative glomerulonephritis.
Synonym: subacute nephritis.
(05 Mar 2000)
immune complex glomerulonephritis Immune complexes are deposited in the renal glomerulus where they bind complement and initiate an inflammatory process attracting neutrophils and macrophages resulting in an alteration of the basement layer of the kidney. The disease state can lead to ultimate destruction of the glomerulus and renal failure.
(05 Mar 2000)
Ellis type 1 glomerulonephritis An obsolete designation for glomerulonephritis presenting as acute glomerulonephritis, followed by complete recovery in most cases, or the development of rapidly progressive glomerulonephritis, or incomplete remission with persistent proteinuria and subsequent development of chronic glomerulonephritis.
Synonym: Ellis type 1 nephritis.
(05 Mar 2000)
Ellis type 2 glomerulonephritis An obsolete designation for glomerulonephritis which is usually not related to preceding bacterial infection; characterised by an insidious onset of the nephrotic syndrome, failure of complete remission, and eventual development of chronic renal failure. The kidneys usually show membranous glomerulonephritis.
Synonym: Ellis type 2 nephritis.
(05 Mar 2000)
extramembranous glomerulonephritis <pathology> A kidney disease that occurs due to inflammation of the kidney glomerulus and its basement membrane. The exact cause is unknown but it appears to be related to the deposition of immune complexes in the basement membrane leading to thickening of the capillary walls. This disorder is a common cause of nephrotic syndrome an is usually how the disease manifests. Risk factors include primary renal disease, malaria, hepatitis B, lupus, syphilis, cancers and non-Hodgkin's lymphomas. Risks also include exposure to some medications such as gold compounds and penicillamine. Mercury, trimethadione and some skin-lightening creams have also been implicated.
Treatment includes systemic corticosteroids and immunosuppressive agents.
(27 Sep 1997)
exudative glomerulonephritis Glomerulonephritis with infiltration of glomeruli by polymorphonuclear leukocytes, occurring in acute glomerulonephritis.
(05 Mar 2000)
focal embolic glomerulonephritis Glomerulonephritis associated with subacute bacterial endocarditis, frequently producing microscopic haematuria without azotemia.
(05 Mar 2000)
focal glomerulonephritis Glomerulonephritis affecting a small proportion of renal glomeruli which commonly presents with haematuria and may be associated with acute upper respiratory infection in young males, not usually due to streptococci; associated with IgA deposits in the glomerular mesangium and may also be associated with systemic disease, as in Henoch-Schonlein purpura.
Synonym: Berger's disease, Berger's focal glomerulonephritis, focal nephritis, IgA nephropathy.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á